Browse > Article
http://dx.doi.org/10.4333/KPS.2006.36.1.039

Controlled Release of Tamsulosin from Nanopore-Forming Granules  

Seo, Seong-Mi (Department of Polymer Engineering, Pukyong National University)
Lee, Hyun-Suk (Department of Information and Biomaterials, Hannam University)
Lee, Jae-Hwi (College of Pharmacy, Chung-Ang University)
Lee, Ha-Young (Nanobiomaterials Laboratory, Korea Research Institute of Chemical Technology)
Lee, Bong (Department of Polymer Engineering, Pukyong National University)
Lee, Hai-Bang (Nanobiomaterials Laboratory, Korea Research Institute of Chemical Technology)
Cho, Sun-Hang (Nanobiomaterials Laboratory, Korea Research Institute of Chemical Technology)
Publication Information
Journal of Pharmaceutical Investigation / v.36, no.1, 2006 , pp. 39-44 More about this Journal
Abstract
Tamsulosin or a salt thereof such as its hydrochloride salt has been known to have an adrenaline ${\alpha}$ receptor blocking action for urethra and prostate areas. It has been widely used as a drug which lowers the prostate pressure and improves urinary disturbance accompanied by prostate-grand enlargement, thus for the treatment of prostatic hyperplasia. To avoid dose-dependent side effects of tamsulosin upon oral administration, the development of sustained-release delivery system is essentially required, that can maintain therapeutic drug levels for a longer period of time. The aim of this study was therefore to formulate sustained-release tamsulosin granules and assess their formulation variables. We designed entric coated sustained-release tamsulosin granules for this purpose. Nano-pores in the outer controlled release membrane were needed in order to obtain initial tamsulosin release even in an acidic environment such as gastric region. In our sustained release osmotic granule system, hydroxypropylmethylcellulose in a drug-containing layer was used as a rate controller. The drug-containing granules were coated with hydroxypropylmethylcellulose phthalate (HPMCP) and Eudragit, along with glycerol triacetate as an aqueous nano-pore former. The release of tamsulosin depended heavily on the type of Eudragit such as RS, RL, NE 30D, used in the formulation of controlled release layer. These results obtained clearly suggest that the sustained-release oral delivery system for tamsulosin could be designed with satisfying drug release profile approved by the Korean Food and Drug Administration.
Keywords
Tamsulosin; Controlled-release; Enteric coated sustained-release;
Citations & Related Records
연도 인용수 순위
  • Reference
1 H.L. Hiltgrewe, Current trends in management of men with lower urinary tract wymptoms and benign prostatic hyperplasia, Urology, 51 (Supp. 4), 1-7 (1998)   DOI   ScienceOn
2 P. Narayan and A. Tewari, Overview of a-blocker therapy for benign prostatic hyperplasia, Urology, 51 (Supp. 4), 38-45 (1998)   DOI   ScienceOn
3 S.A. Kaplan, Minimally invasive alternative therapeutic options for lower urinary tract symptoms, Urology, 51 (Supp. 4), 32-37 (1998)   DOI   ScienceOn
4 M.P. O'Leary, Tamsulosin: current clinical experience, Urology, 58 (Supp. 1), 42-48 (2001)   DOI   ScienceOn
5 M.C. Michel, M.T. Flannery and P. Narayan, Worldwide experience with alfuzosin and tamsulosin, Urology, 58, 508-516 (2001)   DOI   ScienceOn
6 K. Harada, A. Kawaguchi, M. Ohmori and A. Fujimara, Antagonistic activity of tamsulosin against human vascular 1-adrenergic receptor, Clin. Pharmacol. Ther., 67, 405-412 (2000)   DOI   ScienceOn
7 M. Caine, S. Raz and M. Zeigler, Adrenergic and cholonergic receptors in the human prostate, prostatic capsule and bladder neck, Br. J. Urol., 47, 193-202 (1975)   DOI   ScienceOn
8 M. Caine, A. Pfau and S. Perlberg, The use of alpha adrenergic blockers in benign prostatic obstruction, Br. J. Urol., 48, 258-263 (1976)
9 H. Lepor, M. Baumann and E. Shapiro, The stereospecificity of LY253352 for alpha-1 adrenoreceptor binding sites in the brain and prostate, Br. J. Pharmacol., 95, 139-144 (1988)   DOI   ScienceOn
10 S. Kobayashi, R. Tang, E. Shapiro and H. Lepor, Characterization and localization of prostatic alphal adrenoreceptors using radioligand receptor binding on slide-mounted tissue section, J. Urol., 150, 2002-2006 (1993)   DOI
11 G Khang, J. M. Rhee and H. B. Lee, Drug delivery system using osmotic pump : In High Efficiency Anticancer Drug Using Polymeric Biomaterials, H. B. Lee (Ed.), Munundang Publishing Co., Seoul, Korea, pp. 135-154 (2004)
12 S. Dutkiewicz and M. Filipek, Prazosin concentration monitoring in the treatment of prostatic adenoma, Int. Urol. Nephrol., 23, 143-150 (1991)   DOI
13 K.A. Lyseng-Williamson, B. Jarvis and A.J. Wagstaff, Tamsulosin: an update of its role in the management of lower urinary tract symptoms, Drugs, 62, 135-167 (2002)   DOI